Driven by the limitations of the traditional antiarrhythmic pharmacology, current antiarrhythmic research is trying to identify
new avenues for the development of specific and safe antiarrhythmic drugs. One of the most promising approaches in this field is the
amelioration of the abnormal events in cellular Ca2+ handling originating from the dysfunction of ryanodine receptor Ca2+ release
complex (RyR), which is an inevitable key factor in the pathology of myocardial dysfunction, remodeling and arrhythmogenesis.
Accordingly, both in experimental and clinical situations, inhibition of abnormal activity of RyR, regardless of being the primary cause or
a consequence during the pathogenesis appears to exert beneficial effect on disease outcome, including a marked antiarrhythmic defense.
Considerable amount of our knowledge in this field originates from studies using dantrolene, a human drug with RyR stabilizing effect.
Our review summarizes the cardiovascular pharmacology of dantrolene and the results of its use in experimental models of cardiac
diseases, which emphasize a promising perspective for the possible antiarrhythmic application of RyR inhibition in the future.